Tags: Drug.
Gevokizumab is a potent monoclonal antibody developed by XOMA Corporation with unique allosteric modulating properties and the potential to treat patients with a wide variety of inflammatory and other diseases. Gevokizumab binds strongly to interleukin-1 beta (IL-1 beta) a pro-inflammatory cytokine and modulates the cellular signaling events that produce inflammation.